Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Merck
Johnson and Johnson
Harvard Business School
Mallinckrodt
Moodys

Last Updated: December 15, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for TAK-438

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug TAK-438?

TAK-438 is an investigational drug.

There have been 319 clinical trials for TAK-438. The most recent clinical trial was a Phase 3 trial, which was initiated on January 1st 2018.

The most common disease conditions in clinical trials are Diabetes Mellitus, Hypertension, and Diabetes Mellitus, Type 2. The leading clinical trial sponsors are Takeda, Millennium Pharmaceuticals, Inc., and National Cancer Institute (NCI).

There are fifteen US patents protecting this investigational drug and one hundred and thirty-four international patents.

Recent Clinical Trials for TAK-438
TitleSponsorPhase
A Pharmacokinetic and Safety Study of TAK-925 in Participants With Idiopathic HypersomniaMillennium Pharmaceuticals, Inc.Phase 1
A Study of TAK-994 in Participants With Narcolepsy Type 1TakedaPhase 1
A Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics StudyMillennium Pharmaceuticals, Inc.Phase 1

See all TAK-438 clinical trials

Clinical Trial Summary for TAK-438

Top disease conditions for TAK-438
Top clinical trial sponsors for TAK-438

See all TAK-438 clinical trials

US Patents for TAK-438

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
TAK-438   Start Trial 5-aryl-1H-pyrrole-3-carbonitrile and a pharmaceutical product using the same Takeda Pharmaceutical Company Limited (Osaka-Shi, JP)   Start Trial
TAK-438   Start Trial Proton pump inhibitors Takeda Pharmaceutical Company Limited (Osaka, JP)   Start Trial
TAK-438   Start Trial Acid secretion inhibitor Takeda Pharmaceutical Company Limited (Osaka, JP)   Start Trial
TAK-438   Start Trial 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-) aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors Takeda Pharmaceutical Company Limited (Osaka, JP)   Start Trial
TAK-438   Start Trial Proton pump inhibitors Takeda Pharmaceutical Company Limited (Osaka, JP)   Start Trial
TAK-438   Start Trial 1-heterocyclylsulfonyl, 3-aminomethyl, 5-(hetero-) aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors Takeda Pharmaceutical Company Limited (Osaka, JP)   Start Trial
TAK-438   Start Trial 1-heterocyclylsulfonyl, 3-aminomethyl, 5-(hetero-)aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors Takeda Pharmaceutical Company Limited (Osaka, JP)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for TAK-438

Drugname Country Document Number Estimated Expiration Related US Patent
TAK-438 China 102421753 2029-02-25   Start Trial
TAK-438 China 104211618 2029-02-25   Start Trial
TAK-438 China 105524046 2029-02-25   Start Trial
TAK-438 China 108129374 2029-02-25   Start Trial
TAK-438 European Patent Office 2402313 2029-02-25   Start Trial
TAK-438 European Patent Office 2765130 2029-02-25   Start Trial
TAK-438 European Patent Office 3241826 2029-02-25   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
McKesson
Express Scripts
Merck
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.